Does Aetna Cover Skyrizi for Ulcerative Colitis?

If your gastroenterologist has prescribed Skyrizi for ulcerative colitis and you carry Aetna coverage, the practical question is whether your plan will pay and what hoops come first. The short answer is that Aetna does cover risankizumab, the active ingredient in Skyrizi, but coverage runs through a prior authorization process rather than an automatic approval. Aetna is a CVS Health company, so its pharmacy and specialty drug decisions are shaped by CVS Caremark and CVS Specialty, and the clinical rules live in Aetna's published Clinical Policy Bulletins. Understanding how those pieces fit together helps you anticipate what your plan will ask for and how to respond if it says no.

What Skyrizi Is and Why Its UC Status Matters

Skyrizi is the brand name for risankizumab-rzaa, a monoclonal antibody that binds the p19 subunit of interleukin-23 and blocks that cytokine's inflammatory signaling, according to the FDA prescribing information. The same label confirms that the drug is approved for moderately to severely active ulcerative colitis in adults. That ulcerative colitis indication is recent. The FDA approved Skyrizi for ulcerative colitis on June 18, 2024, making it the first IL-23 antagonist cleared for both ulcerative colitis and Crohn's disease. Because the indication is newer than older biologics, many UC patients reach Skyrizi after trying other advanced therapies, which shapes how an insurer evaluates the request.

What the Clinical Evidence Shows

Aetna and other payers anchor coverage decisions to the trial evidence behind an indication, so it helps to know what that evidence says. The approval rested on two phase 3 studies, the 12-week INSPIRE induction trial and the 52-week COMMAND maintenance trial, reported in the Journal of Crohn's and Colitis. In the INSPIRE induction study, clinical remission at week 12 reached 20.3% with risankizumab versus 6.2% with placebo. Patients enrolled had already shown inadequate response or intolerance to conventional or biologic therapy, which mirrors the real-world population reaching for Skyrizi. The 2024 AGA living guideline on moderate-to-severe ulcerative colitis lists risankizumab among recommended advanced therapies and supports early advanced therapy over slow step-up from 5-aminosalicylates, which strengthens the medical-necessity argument your prescriber can make.

How Aetna Handles Skyrizi Coverage

Aetna does not leave Skyrizi off its formulary, but it gates access. The Aetna Clinical Policy Bulletin for risankizumab states that precertification is required for intravenous risankizumab for applicable plan designs, and Skyrizi for ulcerative colitis begins with an intravenous induction course before transitioning to subcutaneous maintenance. The FDA label describes that regimen as three 1,200 mg intravenous induction doses given every four weeks, followed by 180 mg or 360 mg subcutaneously every eight weeks. Because induction is infused and maintenance is self-injected, the two phases can fall under different parts of your benefit, with the medical benefit often covering the infusion and the pharmacy benefit through CVS Caremark covering maintenance. Confirm with your own plan documents how each phase is billed, since this split affects your cost share.

Prior Authorization and Step Therapy Expectations

For the ulcerative colitis indication, Aetna's published bulletin frames the core requirement as treatment of moderately to severely active ulcerative colitis rather than an explicit list of drugs you must fail first, per the Clinical Policy Bulletin. Individual plan designs, however, can layer additional step therapy on top of the bulletin, so your specific Aetna plan may still ask you to document earlier treatments. Practically, that means recording every UC therapy you have tried, the dates, and why each was stopped, whether for inadequate response, loss of response, or intolerance. This documentation matters because the trial population and the AGA guidance both frame risankizumab as a therapy for patients with prior inadequate response, so a clean treatment history supports the request.

Continuation, Denials, and Appeals

Approval is not permanent. To keep covering Skyrizi, Aetna's bulletin asks for evidence that you are responding, such as improvement from baseline in stool frequency, rectal bleeding, C-reactive protein, fecal calprotectin, or endoscopic appearance, according to the Clinical Policy Bulletin. If an initial request is denied, you have appeal rights. Federal rules give members access to an internal appeal and then an independent external review when an insurer upholds a denial, as outlined by the Centers for Medicare and Medicaid Services. A strong appeal pairs your prescriber's letter of medical necessity with your documented treatment history and the disease-activity measures the bulletin names. Read your own denial letter and plan documents closely, because the exact criteria, tiers, and deadlines vary by plan and can change.

The Bottom Line

Aetna covers Skyrizi for ulcerative colitis, but coverage arrives through prior authorization rather than by default. The clinical foundation is solid, with FDA approval in June 2024 and supportive phase 3 data, and Aetna's own Clinical Policy Bulletin centers on confirming moderately to severely active disease and ongoing clinical response. The friction tends to come from plan-level step therapy, the benefit split between infused induction and self-injected maintenance, and the documentation an approval requires. Patients who arrive with a thorough record of prior UC treatments and current disease-activity data give their prescriber the strongest material to clear authorization or to win an appeal. Because plan terms differ, verifying your specific Aetna policy remains the most reliable way to know what you will owe and what you must show.